TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27054919

Group type: EXPERIMENTAL
Intervention: EZH2 expression levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proliferation rate
Number of subjects: 0
Study: 27055247

Group type: EXPERIMENTAL
Intervention: SMT C1100 (50 mg/kg on Days 1 and 11, 50 mg/kg bid on Days 2 to 10)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg bid on Days 2 to 10)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SMT C1100 (100 mg/kg on Days 1 and 11, 100 mg/kg tid on Days 2 to 10)
Number of subjects: 12
Study: 27055466

Group type: EXPERIMENTAL
Intervention: Affected 2010-2012 hs-cTnT lots
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Recalculated 2010-2012 hs-cTnT values
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Corrected assay (re-measured in 2013)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Affected lots using ESC 0 h/1 h algorithm
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Corrected lots using ESC 0 h/1 h algorithm
Number of subjects: 857
Study: 27055731

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus PF-04136309 (500 mg twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: FOLFIRINOX alone
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus PF-04136309
Number of subjects: 47
Study: 27055745

Group type: COMPARATOR
Intervention: Model 2 with biomechanical CT metrics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Jacobian mean
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coefficient of variation (CV) of Jacobian
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CV of strain
Number of subjects: 0
Study: 27055830

Group type: EXPERIMENTAL
Intervention: Transbronchial Cryobiopsy (Cryo-TBB)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Surgical lung biopsy (SLB)
Number of subjects: 51
Study: 27055851

Group type: EXPERIMENTAL
Intervention: Higher Dietary Inflammatory Index (DII)
Number of subjects: 3080

Group type: EXPERIMENTAL
Intervention: Higher DII
Number of subjects: 3080
Study: 27055915

Group type: EXPERIMENTAL
Intervention: Genetic and pharmacological manipulation of the unfolded protein response (UPR) in mouse models of myelinating glia disorders.
Number of subjects: 0
Study: 27056179

Group type: EXPERIMENTAL
Intervention: Adjuvant 3D CRT for breast cancer
Number of subjects: 120
Study: 27056586

Group type: EXPERIMENTAL
Intervention: Reslizumab 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reslizumab 3.0 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27057326

Group type: EXPERIMENTAL
Intervention: Experimental formula containing L. reuteri, GOS (5.50 g/L), and FOS (0.36 g/L)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control formula containing only L. reuteri
Number of subjects: 140
Study: 27057332

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping for about 5 minutes
Number of subjects: 20
Study: 27057335

Group type: EXPERIMENTAL
Intervention: Polluting fuels (kerosene, charcoal, coal, wood, straw, crop waste, dung)
Number of subjects: 65912

Group type: COMPARATOR
Intervention: Clean fuels (electricity, LPG, natural gas, biogas)
Number of subjects: 65912
Study: 27057414

Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 27058744

Group type: EXPERIMENTAL
Intervention: Intra-articular hypertonic dextrose injections (12.5% dextrose, 10 mL, four to six monthly injections)
Number of subjects: 6
Study: 27058874

Group type: EXPERIMENTAL
Intervention: Systemic endovascular cooling to a target of 34.5-35°C, initiated 60-90 min before CEA and maintained during CEA
Number of subjects: 7
Study: 27059507

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraceptives
Number of subjects: 987

Group type: COMPARATOR
Intervention: No medical contraindication
Number of subjects: 987
Study: 27059872

Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 220
Study: 27059973

Group type: EXPERIMENTAL
Intervention: OCT arm
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 84
Study: 27060341

Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg twice daily (maximum 200 mg twice daily) plus background antiretrovirals
Number of subjects: 0
Study: 27061356

Group type: EXPERIMENTAL
Intervention: Children with ASD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Typical controls
Number of subjects: 84
Study: 27061685

Group type: EXPERIMENTAL
Intervention: Postthrombotic limbs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control limbs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dorsal foot vein in affected limbs
Number of subjects: 22

Group type: COMPARATOR
Intervention: Dorsal foot vein in non-affected limbs
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Change in CFV pressure after walking
Number of subjects: 22
Study: 27062495

Group type: EXPERIMENTAL
Intervention: Dynamic infrared thermography (IR)
Number of subjects: 25
Study: 27063005

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study: 27063676

Group type: EXPERIMENTAL
Intervention: SPT-Random (SPT-R)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: SPT-Blocked (SPT-B)
Number of subjects: 4
Study: 27063977

Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg/day (14 days on, 7 days off)
Number of subjects: 41
Study: 27063978

Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg once a day (14 days on, 7 days off)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OTX015 at 120 mg once a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OTX015 at 40 mg twice a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OTX015 at 80 mg once a day
Number of subjects: 45
Study: 27064032

Group type: EXPERIMENTAL
Intervention: TRI at 0 cm from the radius styloid process
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: TRI at 1 cm from the radius styloid process
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: TRI with arterial diameter to sheath diameter ratio ≤1
Number of subjects: 606

Group type: COMPARATOR
Intervention: TRI at 2-5 cm from the radius styloid process
Number of subjects: 606
Study: 27064675

Group type: EXPERIMENTAL
Intervention: Metabolically sick participants (defined by the presence of two or more metabolic abnormalities)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Overweight and normal weight patients who were metabolically healthy
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Obesity (compared to the composite group of normal weight and overweight patients)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Metabolically abnormal phenotype
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Absence of metabolic abnormality
Number of subjects: 1002
Study: 27065848

Group type: EXPERIMENTAL
Intervention: RRx-001
Number of subjects: 1
Study: 27065849

Group type: EXPERIMENTAL
Intervention: RRx-001 followed by carboplatin and etoposide
Number of subjects: 1
Study: 27065913

Group type: EXPERIMENTAL
Intervention: Liking norm condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegetable variety condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health message condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Descriptive norm condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral control condition
Number of subjects: 0
Study: 27066336

Group type: EXPERIMENTAL
Intervention: Evolocumab self-administered biweekly over 6 weeks (n=149)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Evolocumab self-administered monthly over 12 weeks (n=164)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Evolocumab self-administration
Number of subjects: 313

Group type: COMPARATOR
Intervention: Evolocumab (both dosing schedules and devices)
Number of subjects: 313
Study: 27066461

Group type: EXPERIMENTAL
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 1987

Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Definitive RCT
Number of subjects: 1987

Group type: EXPERIMENTAL
Intervention: Patients with hydroureteronephrosis
Number of subjects: 1987
Study: 27066464

Group type: EXPERIMENTAL
Intervention: Low-dose methylprednisolone therapy (MPT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 35
Study: 27066824

Group type: EXPERIMENTAL
Intervention: Knowledge of heart-healthy behaviors
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Catalysts for behavior change
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Barriers to adopting healthy habits
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Facilitators for healthy behaviors
Number of subjects: 54
Study: 27067081

Group type: EXPERIMENTAL
Intervention: Desmopressin treatment
Number of subjects: 30
Study: 27067321

Group type: EXPERIMENTAL
Intervention: Pod-intravaginal ring (pod-IVR) delivering a combination of TDF and MVC
Number of subjects: 0
Study: 27067336

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (SXT) administered orally at a dose of 960 mg once daily
Number of subjects: 12
Study: 27067896

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation initiated in the emergency department (LOV-ED)
Number of subjects: 513

Group type: COMPARATOR
Intervention: Pre-intervention control group
Number of subjects: 513
Study: 27068030

Group type: EXPERIMENTAL
Intervention: Standard of care sternal closure plus PRP
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard of care sternal closure
Number of subjects: 2000
Study: 27068396

Group type: EXPERIMENTAL
Intervention: Artesunate-Mefloquine (ASMQ) fixed-dose combination
Number of subjects: 162
Study: 27068662

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including preparation, process, and patient-centeredness
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Retention strategies including flexible protocol and stipends
Number of subjects: 746
Study: 27070726

Group type: COMPARATOR
Intervention: Definite PCD (205 participants)
Number of subjects: 534
Study: 27071063

Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN), dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broccoli sprout homogenate (BSH) containing sulforaphane (SFN).
Number of subjects: 0
Study: 27071399

Group type: EXPERIMENTAL
Intervention: Proactive care (mailed invitation followed by telephone outreach, offer of smoking cessation services, access to pharmacotherapy)
Number of subjects: 3006

Group type: EXPERIMENTAL
Intervention: Proactive care
Number of subjects: 3006

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3006
Study: 27071497

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study: 27071522

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus romidepsin (GEMRO regimen)
Number of subjects: 20
Study: 27071922

Group type: EXPERIMENTAL
Intervention: Binimetinib 45 mg BID
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Binimetinib 30 mg BID
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Binimetinib (both doses)
Number of subjects: 21
Study: 27072861

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle (nonsmoker, physically active ≥150 min/wk, BMI 18.5-25 kg/m², adherence to a modified Mediterranean diet)
Number of subjects: 64979

Group type: EXPERIMENTAL
Intervention: All 4 healthy behaviors
Number of subjects: 64979
Study: 27072954

Group type: EXPERIMENTAL
Intervention: Transdermal latrepirdine (5 mg and 10 mg for EMs)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral latrepirdine (8.14 mg)
Number of subjects: 19
Study: 27073910

Group type: EXPERIMENTAL
Intervention: Automated MSCT-ST (A-MSCT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Manual MSCT-ST (M-MSCT)
Number of subjects: 125
Study: 27074035

Group type: EXPERIMENTAL
Intervention: Comprehensive Primary Care Initiative practices
Number of subjects: 497
Study: 27074725

Group type: EXPERIMENTAL
Intervention: Elective abdominal surgery
Number of subjects: 604
Study: 27074795

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) abatacept (single dose at baseline) followed by 4 weeks break and then continuation of weekly SC abatacept from day 28.
Number of subjects: 49
Study: 27075016

Group type: EXPERIMENTAL
Intervention: Continuous olaparib and irinotecan every 3 weeks (Part A)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intermittent olaparib and irinotecan every 2 weeks (Part B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intermittent olaparib and irinotecan (Part B)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both olaparib and irinotecan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combination of olaparib and irinotecan
Number of subjects: 25
Study: 27075906

Group type: EXPERIMENTAL
Intervention: Maternal dietary vitamin B-12 intake during pregnancy
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Serum vitamin B-12 concentrations
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Elevated MMA (>271 nmol/L)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Fetal genetic polymorphisms
Number of subjects: 368
Study: 27076187

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) monitoring
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Mid-region fragment of pro-adrenomedullin (MR-proADM)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Temperature and white cell count
Number of subjects: 138

Group type: COMPARATOR
Intervention: Non-infected controls (N = 70)
Number of subjects: 138
Study: 27076275

Group type: EXPERIMENTAL
Intervention: 36 single-nucleotide polymorphisms (SNPs) associated with childhood BMI gain
Number of subjects: 5906

Group type: EXPERIMENTAL
Intervention: Cumulative allelic risk score (ARS) for childhood
Number of subjects: 5906

Group type: EXPERIMENTAL
Intervention: 9 single-nucleotide polymorphisms (SNPs) associated with adulthood BMI change
Number of subjects: 5906
Study: 27076486

Group type: EXPERIMENTAL
Intervention: PAM (Fitbit One)
Number of subjects: 95
Study: 27076496

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (NFPP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 140
Study: 27076600

Group type: EXPERIMENTAL
Intervention: Aldosterone Antagonist (AA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Renin-Guided Therapy (RGT)
Number of subjects: 44
Study: 27076940

Group type: EXPERIMENTAL
Intervention: S-1 at 60 mg/m(2)/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-1 at 70 mg/m(2)/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-1 at 80 mg/m(2)/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S-1 with concurrent radiotherapy
Number of subjects: 12
Study: 27077906

Group type: EXPERIMENTAL
Intervention: Early extubation within one hour after skin closure and close neurological monitoring
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Early extubation within one hour
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Patients extubated within one hour
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Patients with delayed extubation
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Failure to extubate within one hour
Number of subjects: 492
Study: 27078728

Group type: EXPERIMENTAL
Intervention: Sunitinib, a small tyrosine kinase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab, a therapeutic antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurosurgical resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27079291

Group type: EXPERIMENTAL
Intervention: Individual interviews using a semi-structured questionnaire
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cultural scripts related to body weight
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Evaluation of cultural scripts by health care providers
Number of subjects: 29
Study: 27079334

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy with aspirin and clopidogrel after PCI
Number of subjects: 4190

Group type: EXPERIMENTAL
Intervention: Risk score models developed from baseline clinical variables
Number of subjects: 4190
Study: 27080216

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dabrafenib
Number of subjects: 84
Study: 27080574

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 374
Study: 27080930

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27080929

Group type: EXPERIMENTAL
Intervention: Anakinra (recombinant human IL-1 receptor antagonist) administered by daily subcutaneous injection for 2-6 weeks
Number of subjects: 30
Study: 27081020

Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with native T1 mapping
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with T2 mapping
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with ECV calculation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with Lake Louise criteria (LLC)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with native T1 mapping
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with ECV calculation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 3.0-T imaging with Lake Louise criteria (LLC)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.5-T imaging with T2 mapping in chronic symptoms
Number of subjects: 129
Study: 27081022

Group type: EXPERIMENTAL
Intervention: T1 mapping in patients with HFpEF
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ECV greater than the median in HFpEF cohort
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ECV below the median in HFpEF cohort
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analyses of ECV in HFpEF
Number of subjects: 36
Study: 27082506

Group type: EXPERIMENTAL
Intervention: Elective Cesarean Section (ECS)
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Nonelective Cesarean Section (NECS)
Number of subjects: 2297

Group type: COMPARATOR
Intervention: Vaginal Delivery
Number of subjects: 2297

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2297
Study: 27082828

Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 2
Study: 27083333

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Irinotecan plus oxaliplatin (IROX)
Number of subjects: 97
Study: 27083775

Group type: EXPERIMENTAL
Intervention: Germline analysis through tumor-germline dyad sequencing
Number of subjects: 439
Study: 27084275

Group type: EXPERIMENTAL
Intervention: Pathogenic or likely pathogenic germline variants screening
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pathogenic germline BRCA2 variants screening
Number of subjects: 71
Study: 27084277

Group type: EXPERIMENTAL
Intervention: Isotoxic intensity modulated radiotherapy (IMRT)
Number of subjects: 35
Study: 27084282

Group type: EXPERIMENTAL
Intervention: Nurse educational oral feeding programme
Number of subjects: 120
Study: 27084281

Group type: EXPERIMENTAL
Intervention: Antirheumatic treatment (biologicals and/or conventional synthetic DMARDs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Baseline US scores
Number of subjects: 100
Study: 27084286

Group type: EXPERIMENTAL
Intervention: Free cataract surgery
Number of subjects: 833
Study: 27084348

Group type: EXPERIMENTAL
Intervention: Etarfolatide (99m)Tc-EC20 imaging technique
Number of subjects: 25
Study: 27084507

Group type: EXPERIMENTAL
Intervention: Azacitidine front-line
Number of subjects: 339
Study: 27084534

Group type: EXPERIMENTAL
Intervention: Stage-based treatment approach
Number of subjects: 367
Study: 27084653

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Proton Therapy (IMPT)
Number of subjects: 50
Study: 27084692

Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/d for 16 weeks, augmented with aripiprazole 2-10 mg/d if clinically warranted after 8 weeks
Number of subjects: 134

Group type: COMPARATOR
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 134
Study: 27085172

Group type: EXPERIMENTAL
Intervention: bivalent oral polio vaccine (bOPV)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: bOPV
Number of subjects: 320
Study: 27086090

Group type: EXPERIMENTAL
Intervention: trNS
Number of subjects: 20
Study: 27086275

Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in men
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in high risk women (2 or more HERDOO2 points)
Number of subjects: 663

Group type: EXPERIMENTAL
Intervention: Short-term anticoagulation (3-6 months) in low risk women (1 or 0 HERDOO2 points)
Number of subjects: 663
Study: 27087007

Group type: EXPERIMENTAL
Intervention: 75 mg intravenous mepolizumab (MENSA)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: 100 mg subcutaneous mepolizumab (SIRIUS)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: mepolizumab (both studies)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study: 27087478

Group type: EXPERIMENTAL
Intervention: Population-based HIV testing and streamlined ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 27087519

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily plus pantoprazole 40 mg twice daily for 6 months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sitagliptin plus pantoprazole
Number of subjects: 8
Study: 27087946

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia
Number of subjects: 330

Group type: COMPARATOR
Intervention: GERD
Number of subjects: 330
Study: 27088163

Group type: EXPERIMENTAL
Intervention: Protocol-based classification of CLRD cases and exacerbations
Number of subjects: 216
Study: 27088859

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg/d for 8 weeks
Number of subjects: 31
Study: 27089287

Group type: EXPERIMENTAL
Intervention: Multimodal sensory stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Median nerve stimulation
Number of subjects: 0